Compositions and methods for regulating cancer-related signaling pathways

Abstract

The use of luteinizing hormone receptor (LHR) as a treatment target in cancer is provided. Data demonstrates that LHR plays an important role in androgen synthesis and signaling pathways critical for prostate cancer progression. When LHR is silenced, there is a significant downregulation of androgen receptor (AR) mRNA and protein expression with a subsequent suppression of PSA expression. Data suggesting that the LH-LHR signaling cascade may be an upstream and viable therapeutic target in castration-resistant prostate cancer (CRPC) is presented.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to View More

AI Technical Summary

Benefits of technology

The patent text discusses the impact of LH exposure on prostate cancer cells. The researchers found that LH increased the survival of these cells and also led to the production of testosterone. They also tested the effect of silencing LHR expression and found that it impacted several key survival pathways in prostate cancer. The technical effect of the patent is the demonstration of a potential therapeutic effect of LH in treating prostate cancer.

Problems solved by technology

The technical problem addressed in this patent text relates to understanding how aberrant androgen signals contribute to the growth and spread of prostate cancer, particularly during advanced stages where traditional treatments such as androgen deprivation have limited effectiveness. More specifically, the text discusses the potential role of regulatory mechanisms involved in controlling tumor-related androgen production, which may provide new opportunities for developing more effective therapies against prostate cancer.

Images